NCT03739554 2024-01-25CYC065 CDK Inhibitor and Venetoclax Study in Relapsed/Refractory CLLCyclacel Pharmaceuticals, Inc.Phase 1 Completed5 enrolled
NCT04983810 2024-01-25A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and LymphomaCyclacel Pharmaceuticals, Inc.Phase 1/2 Unknown330 enrolled